ATLASTaysha Gene Therapies (TSHA) Q3 2026 earnings results
Taysha Gene Therapies (TSHA) reported EPS of -$0.09 against an analyst estimate of -$0.12: a beat of $0.03 (25.0%). The quarter ended Sep 30, 2026; the company reported on Thursday, November 12, 2026, before the open.
Status: Confirmed · 06:00 ET, Nov 12 · revised Nov 12, 2026 · Source: EODHD (calendar and fundamentals, cross-checked)
Get an email before and after Taysha Gene Therapies reports, free with your ATLAS account
Earnings alerts are a free benefit of your ATLAS account. The company goes to your watchlist and we email you when it reports. Google signup is one click.
Create free accountTSHA Q3 2026 results at a glance
| EPS reported | -$0.09 |
|---|---|
| EPS estimate | -$0.12 |
| Surprise | Beat · +$0.03 (+25.0%) |
| Quarter ended | Sep 30, 2026 |
| Reported | Nov 12, 2026, before the open |
| Status | Confirmed · 06:00 ET, Nov 12 |
EPS is as supplied by EODHD, in US dollars per share; whether it is adjusted or GAAP follows that source. This is Taysha Gene Therapies’s Q3 2026, a calendar-year company.
Taysha Gene Therapies EPS surprise history: last 5 quarters
Taysha Gene Therapies beat the EPS estimate in 3 of its last 5 reports, with an average surprise of +17.5%.
| Report date | EPS est. | EPS actual | Surprise | Result | Move* |
|---|---|---|---|---|---|
| Nov 12, 2026 | -$0.12 | -$0.09 | +35.7% | Beat | – |
| Aug 11, 2026 | -$0.11 | -$0.13 | -18.2% | Miss | +0.6% |
| May 21, 2026 | $2.60 | $3.64 | +40.0% | Beat | 0.0% |
| Mar 19, 2026 | -$0.10 | -$0.07 | +30.0% | Beat | -1.1% |
| Nov 4, 2025 | -$0.09 | -$0.09 | 0.0% | In line | -9.6% |
*Move: change in the closing price from the last close before the report day to the close the day after it. It is filled in a few trading days after each report.
TSHA stock reaction to the report
TSHA moved -1.64% in the first session that reflects the report (close of Nov 11, 2026 $4.28 to close of Nov 12, 2026 $4.21).
Next TSHA earnings report
Taysha Gene Therapies has not announced its next earnings date yet. This page shows a date only once it is confirmed. See the TSHA earnings calendar.
ATLAS fair value and signal for TSHA
| Last price | $4.12 (-2.3%) |
|---|---|
| Chance of a higher close in 1 month | 47% (normal range $3.60–$4.58) |
These are model outputs from the same valuation and calibrated model as the Taysha Gene Therapies stock page. They describe an ordinary period and are not a forecast of any particular outcome.
Taysha Gene Therapies Q3 2026 earnings: frequently asked questions
Did Taysha Gene Therapies beat earnings estimates for Q3 2026?
Taysha Gene Therapies reported EPS of -$0.09 against an analyst estimate of -$0.12: a beat of $0.03 (25.0%).
When did Taysha Gene Therapies report Q3 2026 results?
Taysha Gene Therapies reported on Thursday, November 12, 2026, before the open, for the quarter ended Wednesday, September 30, 2026.
How often does TSHA beat EPS estimates?
In its last 5 reports with a recorded result, Taysha Gene Therapies beat the EPS estimate 3 times; the average surprise was +17.5%. Past results do not predict the next one.
How does ATLAS confirm a result?
A result is published only after it is cross-checked: the EODHD earnings calendar and the EODHD fundamentals feed must show the same EPS for the same fiscal period, or the same value must appear in two consecutive checks. Unconfirmed figures are never published. If the figures are revised later, this page updates.
Educational information, not investment advice. Disclaimer